Supplementary Figure S4 from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target

Takuma Yoshimura; Takashi Kamatani; Aki Ookubo; Mio Takahashi; Manabu Itoh; Toshiki Ebisudani; Yohei Masugi; Tomomi Toyonaga; Junko Hamamoto; Keiko Saotome; Kensuke Sakai; Tomoko Yoshihama; Nobuko Moritoki; Shinsuke Shibata; Hiroyuki Yasuda; Toshiro Sato; Taka-Aki Sato; Daisuke Aoki; Wataru Yamagami; Tatsuhiko Tsunoda; Tatsuyuki Chiyoda

doi:10.1158/2767-9764.29645820

Key Points

High-throughput drug screening uncovered vulnerabilities in clear cell ovarian cancer organoids to proteasome inhibitors.
Gene set enrichment analysis indicated significant differences in signaling pathways between AGR2-knockout organoids and controls.
Pathways affected included WNT signaling, P53 pathway, and epithelial-mesenchymal transition.
Identifying AGR2 as a therapeutic target may help develop more effective treatments for clear cell ovarian cancer.

Implication

Gene set enrichment analysis reveals distinct pathways in AGR2-knockout organoids, suggesting new therapeutic targets for clear cell ovarian cancer.

Abstract

Box plot showing Single-sample Gene Set Enrichment Analysis (ssGSEA) scores significantly different between AGR2-knockout organoids and controls (HALLMARK_WNT_BETA_CATENIN_SIGNALING, HALLMARK_P53_PATHWAY, HALLMARK_PEROXISOME, HALLMARK_EPITHELIAL_MESENYCHYMAL_TRANSITION, HALLMARK_NOTCH_SIGNALING, HALLMARK_COAGULATION, HALLMARK_PROTEIN_SECRETION, HALLMARK_HYPOXIA). CCC, clear cell ovarian cancer; cont., control; HGSC, high-grade serous ovarian cancer

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Yoshimura et al. (2025) studied this question.

synapsesocial.com/papers/689a0f8de6551bb0af8d0d55 https://doi.org/10.1158/2767-9764.29645820

View at Publisher

Ask AI

Bookmark

Share

Supplementary Figure S4 from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target

Key Points

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure S4 from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers